No / The identification of an agent that is selectively activated by a cytochrome P450 (CYP) has the potential for tissue specific dose intensification as a means of significantly improving its therapeutic value. Towards this goal, we disclose evidence for the pathway of activation of a duocarmycin analogue, ICT2700, which targets CYP1A1 for biological activity.
Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/6138 |
Date | January 2011 |
Creators | Pors, Klaus, Loadman, Paul, Shnyder, Steven, Sutherland, Mark, Sheldrake, Helen M., Guino, M., Kiakos, K., Hartley, J.A., Searcey, M., Patterson, Laurence H. |
Source Sets | Bradford Scholars |
Language | English |
Detected Language | English |
Type | Article, No full-text in the repository |
Page generated in 0.0014 seconds